25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Pharma Equity Group A/S Cl A
Buy, Hold or Sell?

Let's analyze Pharma Equity Group A/S Cl A together

I guess you are interested in Pharma Equity Group A/S Cl A. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Pharma Equity Group A/S Cl A. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Pharma Equity Group A/S Cl A

I send you an email if I find something interesting about Pharma Equity Group A/S Cl A.

1. Quick Overview

1.1. Quick analysis of Pharma Equity Group A/S Cl A (30 sec.)










1.2. What can you expect buying and holding a share of Pharma Equity Group A/S Cl A? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr0.02
Expected worth in 1 year
kr0.00
How sure are you?
23.5%

+ What do you gain per year?

Total Gains per Share
kr-0.02
Return On Investment
-15.3%

For what price can you sell your share?

Current Price per Share
kr0.16
Expected price per share
kr0.15 - kr0.1995
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Pharma Equity Group A/S Cl A (5 min.)




Live pricePrice per Share (EOD)
kr0.16
Intrinsic Value Per Share
kr-0.08 - kr-0.09
Total Value Per Share
kr-0.05 - kr-0.07

2.2. Growth of Pharma Equity Group A/S Cl A (5 min.)




Is Pharma Equity Group A/S Cl A growing?

Current yearPrevious yearGrowGrow %
How rich?$3.6m$7.2m-$2m-40.5%

How much money is Pharma Equity Group A/S Cl A making?

Current yearPrevious yearGrowGrow %
Making money-$1m$29.5k-$1m-102.8%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Pharma Equity Group A/S Cl A (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Pharma Equity Group A/S Cl A?

Welcome investor! Pharma Equity Group A/S Cl A's management wants to use your money to grow the business. In return you get a share of Pharma Equity Group A/S Cl A.

First you should know what it really means to hold a share of Pharma Equity Group A/S Cl A. And how you can make/lose money.

Speculation

The Price per Share of Pharma Equity Group A/S Cl A is kr0.16. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Pharma Equity Group A/S Cl A.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Pharma Equity Group A/S Cl A, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr0.02. Based on the TTM, the Book Value Change Per Share is kr-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is kr0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Pharma Equity Group A/S Cl A.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps0.00-0.4%0.00-0.5%0.000.0%0.00-0.2%0.00-0.1%
Usd Book Value Change Per Share0.00-0.4%0.00-0.5%0.000.2%0.00-0.6%0.000.4%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.00-0.4%0.00-0.5%0.000.2%0.00-0.6%0.000.4%
Usd Price Per Share0.04-0.05-0.07-0.06-0.22-
Price to Earnings Ratio-15.50--17.42--32.64--5,425.89--4,078.97-
Price-to-Total Gains Ratio-62.01--68.70-82.44--4.53--3,472.34-
Price to Book Ratio14.03-12.83-11.32-11.93-17.29-
Price-to-Total Gains Ratio-62.01--68.70-82.44--4.53--3,472.34-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0224
Number of shares44642
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (44642 shares)-38.20-41.33
Gains per Year (44642 shares)-152.82-165.30
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-153-1630-165-175
20-306-3160-331-340
30-458-4690-496-505
40-611-6220-661-670
50-764-7750-827-835
60-917-9280-992-1000
70-1070-10810-1157-1165
80-1223-12340-1322-1330
90-1375-13870-1488-1495
100-1528-15400-1653-1660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.08.00.011.1%1.08.00.011.1%1.016.00.05.9%2.034.00.05.6%
Book Value Change Per Share0.04.00.00.0%2.06.01.022.2%2.06.01.022.2%4.012.01.023.5%8.026.02.022.2%
Dividend per Share0.00.04.00.0%0.00.09.00.0%0.00.09.00.0%0.00.017.00.0%0.00.036.00.0%
Total Gains per Share0.04.00.00.0%2.06.01.022.2%2.06.01.022.2%4.012.01.023.5%8.026.02.022.2%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Pharma Equity Group A/S Cl A compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.005-0.006+28%0.002-303%-0.007+39%0.005-201%
Book Value Per Share--0.0210.030-30%0.042-50%0.036-42%0.049-57%
Current Ratio--1.9242.055-6%1.965-2%1.788+8%1.038+85%
Debt To Asset Ratio--0.6620.541+22%0.344+93%0.431+54%84.835-99%
Debt To Equity Ratio--1.9591.285+52%0.524+274%0.862+127%0.564+248%
Dividend Per Share----0%-0%-0%-0%
Eps---0.005-0.006+30%0.000-2878%-0.003-44%-0.002-66%
Free Cash Flow Per Share---0.003-0.004+19%-0.002-47%-0.002-24%-0.002-47%
Free Cash Flow To Equity Per Share---0.001-0.001-50%0.001-218%0.000-737%0.000-99%
Gross Profit Margin--1.0211.010+1%1.000+2%1.004+2%1.002+2%
Intrinsic Value_10Y_max---0.087--------
Intrinsic Value_10Y_min---0.076--------
Intrinsic Value_1Y_max---0.009--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max---0.028--------
Intrinsic Value_3Y_min---0.027--------
Intrinsic Value_5Y_max---0.046--------
Intrinsic Value_5Y_min---0.042--------
Market Cap196406394.880-85%363351830.528459099948.032-21%589986397.120-38%519453996.459-30%1968649171.622-82%
Net Profit Margin----0%-0%-0%-5.1790%
Operating Margin----0%-0%-0%-4.2350%
Operating Ratio----0%-0%-0%4.166-100%
Pb Ratio7.583-85%14.02912.829+9%11.317+24%11.931+18%17.292-19%
Pe Ratio-8.378+46%-15.499-17.424+12%-32.640+111%-5425.887+34909%-4078.974+26218%
Price Per Share0.160-85%0.2960.374-21%0.481-38%0.423-30%1.604-82%
Price To Free Cash Flow Ratio-12.684+46%-23.466-29.341+25%-20.600-12%-5481.289+23258%-82353.602+350844%
Price To Total Gains Ratio-33.516+46%-62.005-68.700+11%82.436-175%-4.533-93%-3472.342+5500%
Quick Ratio--0.0271.559-98%1.937-99%1.554-98%0.910-97%
Return On Assets---0.076-0.095+24%0.007-1130%-0.039-49%-0.167+118%
Return On Equity---0.226-0.218-4%0.012-1963%-0.091-60%-0.051-77%
Total Gains Per Share---0.005-0.006+28%0.002-303%-0.007+39%0.005-201%
Usd Book Value--3626000.0005175205.000-30%7269325.000-50%6220915.556-42%8467587.059-57%
Usd Book Value Change Per Share---0.001-0.001+28%0.000-303%-0.001+39%0.001-201%
Usd Book Value Per Share--0.0030.004-30%0.006-50%0.005-42%0.007-57%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.001-0.001+30%0.000-2878%0.000-44%0.000-66%
Usd Free Cash Flow---541940.000-644245.000+19%-285250.000-47%-413146.782-24%-287258.885-47%
Usd Free Cash Flow Per Share--0.000-0.001+19%0.000-47%0.000-24%0.000-47%
Usd Free Cash Flow To Equity Per Share--0.0000.000-50%0.000-218%0.000-737%0.000-99%
Usd Market Cap27496895.283-85%50869256.27464273992.724-21%82598095.597-38%72723559.504-30%275610884.027-82%
Usd Price Per Share0.022-85%0.0410.052-21%0.067-38%0.059-30%0.225-82%
Usd Profit---820540.000-1065085.000+30%29540.000-2878%-460280.504-44%-279962.620-66%
Usd Revenue----0%-0%-0%9643.529-100%
Usd Total Gains Per Share---0.001-0.001+28%0.000-303%-0.001+39%0.001-201%
 EOD+3 -5MRQTTM+14 -16YOY+3 -275Y+7 -2310Y+8 -24

3.3 Fundamental Score

Let's check the fundamental score of Pharma Equity Group A/S Cl A based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-8.378
Price to Book Ratio (EOD)Between0-17.583
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.027
Current Ratio (MRQ)Greater than11.924
Debt to Asset Ratio (MRQ)Less than10.662
Debt to Equity Ratio (MRQ)Less than11.959
Return on Equity (MRQ)Greater than0.15-0.226
Return on Assets (MRQ)Greater than0.05-0.076
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Pharma Equity Group A/S Cl A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.303
Ma 20Greater thanMa 500.165
Ma 50Greater thanMa 1000.197
Ma 100Greater thanMa 2000.235
OpenGreater thanClose0.160
Total0/5 (0.0%)

4. In-depth Analysis

4.1 About Pharma Equity Group A/S Cl A

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouchitis; and RNX-051 for the treatment of colorectal cancer and colon adenoma. The company was incorporated in 2002 and is based in Hørsholm, Denmark.

Fundamental data was last updated by Penke on 2024-11-23 13:18:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Pharma Equity Group A/S Cl A earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that kr0.00 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-517.9%+517.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--115.9%+115.9%
TTM--210.8%+210.8%
YOY--214.5%+214.5%
5Y--342.2%+342.2%
10Y-517.9%-464.5%-53.4%
4.3.1.2. Return on Assets

Shows how efficient Pharma Equity Group A/S Cl A is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • -7.6% Return on Assets means that Pharma Equity Group A/S Cl A generated kr-0.08 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Pharma Equity Group A/S Cl A:

  • The MRQ is -7.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -9.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-9.5%+1.9%
TTM-9.5%YOY0.7%-10.3%
TTM-9.5%5Y-3.9%-5.6%
5Y-3.9%10Y-16.7%+12.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-11.1%+3.5%
TTM-9.5%-11.7%+2.2%
YOY0.7%-11.3%+12.0%
5Y-3.9%-12.7%+8.8%
10Y-16.7%-14.3%-2.4%
4.3.1.3. Return on Equity

Shows how efficient Pharma Equity Group A/S Cl A is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • -22.6% Return on Equity means Pharma Equity Group A/S Cl A generated kr-0.23 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Pharma Equity Group A/S Cl A:

  • The MRQ is -22.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -21.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-22.6%TTM-21.8%-0.8%
TTM-21.8%YOY1.2%-23.0%
TTM-21.8%5Y-9.1%-12.6%
5Y-9.1%10Y-5.1%-4.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-22.6%-14.2%-8.4%
TTM-21.8%-15.8%-6.0%
YOY1.2%-13.9%+15.1%
5Y-9.1%-18.5%+9.4%
10Y-5.1%-19.5%+14.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Pharma Equity Group A/S Cl A.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Pharma Equity Group A/S Cl A is operating .

  • Measures how much profit Pharma Equity Group A/S Cl A makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated kr0.00  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-423.5%+423.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--258.6%+258.6%
TTM--318.3%+318.3%
YOY--224.0%+224.0%
5Y--386.5%+386.5%
10Y-423.5%-497.6%+74.1%
4.3.2.2. Operating Ratio

Measures how efficient Pharma Equity Group A/S Cl A is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are kr0.00 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y4.166-4.166
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.594-2.594
TTM-3.360-3.360
YOY-3.299-3.299
5Y-4.788-4.788
10Y4.1666.528-2.362
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Pharma Equity Group A/S Cl A.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Pharma Equity Group A/S Cl A is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.92 means the company has kr1.92 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 1.924. The company is able to pay all its short-term debts. +1
  • The TTM is 2.055. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.924TTM2.055-0.132
TTM2.055YOY1.965+0.090
TTM2.0555Y1.788+0.267
5Y1.78810Y1.038+0.750
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9243.658-1.734
TTM2.0553.874-1.819
YOY1.9654.672-2.707
5Y1.7885.960-4.172
10Y1.0386.277-5.239
4.4.3.2. Quick Ratio

Measures if Pharma Equity Group A/S Cl A is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • A Quick Ratio of 0.03 means the company can pay off kr0.03 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 0.027. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 1.559. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ0.027TTM1.559-1.532
TTM1.559YOY1.937-0.377
TTM1.5595Y1.554+0.005
5Y1.55410Y0.910+0.644
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0273.104-3.077
TTM1.5593.426-1.867
YOY1.9374.498-2.561
5Y1.5545.933-4.379
10Y0.9106.426-5.516
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Pharma Equity Group A/S Cl A.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Pharma Equity Group A/S Cl A assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Pharma Equity Group A/S Cl A to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66 means that Pharma Equity Group A/S Cl A assets are financed with 66.2% credit (debt) and the remaining percentage (100% - 66.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 0.662. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.541. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.662TTM0.541+0.121
TTM0.541YOY0.344+0.197
TTM0.5415Y0.431+0.110
5Y0.43110Y84.835-84.404
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6620.354+0.308
TTM0.5410.345+0.196
YOY0.3440.311+0.033
5Y0.4310.366+0.065
10Y84.8350.382+84.453
4.5.4.2. Debt to Equity Ratio

Measures if Pharma Equity Group A/S Cl A is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • A Debt to Equity ratio of 195.9% means that company has kr1.96 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Pharma Equity Group A/S Cl A:

  • The MRQ is 1.959. The company is just able to pay all its debts with equity.
  • The TTM is 1.285. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.959TTM1.285+0.674
TTM1.285YOY0.524+0.761
TTM1.2855Y0.862+0.423
5Y0.86210Y0.564+0.298
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9590.398+1.561
TTM1.2850.437+0.848
YOY0.5240.378+0.146
5Y0.8620.452+0.410
10Y0.5640.495+0.069
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Pharma Equity Group A/S Cl A generates.

  • Above 15 is considered overpriced but always compare Pharma Equity Group A/S Cl A to the Biotechnology industry mean.
  • A PE ratio of -15.50 means the investor is paying kr-15.50 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Pharma Equity Group A/S Cl A:

  • The EOD is -8.378. Based on the earnings, the company is expensive. -2
  • The MRQ is -15.499. Based on the earnings, the company is expensive. -2
  • The TTM is -17.424. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.378MRQ-15.499+7.121
MRQ-15.499TTM-17.424+1.925
TTM-17.424YOY-32.640+15.217
TTM-17.4245Y-5,425.887+5,408.464
5Y-5,425.88710Y-4,078.974-1,346.913
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-8.378-2.160-6.218
MRQ-15.499-2.428-13.071
TTM-17.424-3.145-14.279
YOY-32.640-3.304-29.336
5Y-5,425.887-6.080-5,419.807
10Y-4,078.974-6.625-4,072.349
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Pharma Equity Group A/S Cl A:

  • The EOD is -12.684. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -23.466. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -29.341. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-12.684MRQ-23.466+10.782
MRQ-23.466TTM-29.341+5.875
TTM-29.341YOY-20.600-8.742
TTM-29.3415Y-5,481.289+5,451.947
5Y-5,481.28910Y-82,353.602+76,872.314
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-12.684-2.980-9.704
MRQ-23.466-3.295-20.171
TTM-29.341-3.682-25.659
YOY-20.600-4.523-16.077
5Y-5,481.289-8.162-5,473.127
10Y-82,353.602-9.239-82,344.363
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Pharma Equity Group A/S Cl A is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 14.03 means the investor is paying kr14.03 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Pharma Equity Group A/S Cl A:

  • The EOD is 7.583. Based on the equity, the company is overpriced. -1
  • The MRQ is 14.029. Based on the equity, the company is expensive. -2
  • The TTM is 12.829. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD7.583MRQ14.029-6.446
MRQ14.029TTM12.829+1.200
TTM12.829YOY11.317+1.513
TTM12.8295Y11.931+0.899
5Y11.93110Y17.292-5.361
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.5831.869+5.714
MRQ14.0292.027+12.002
TTM12.8292.365+10.464
YOY11.3172.419+8.898
5Y11.9313.668+8.263
10Y17.2924.362+12.930
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. All numbers in thousands.

Summary
Total Assets76,637
Total Liabilities50,737
Total Stockholder Equity25,900
 As reported
Total Liabilities 50,737
Total Stockholder Equity+ 25,900
Total Assets = 76,637

Assets

Total Assets76,637
Total Current Assets61,762
Long-term Assets14,875
Total Current Assets
Cash And Cash Equivalents 863
Other Current Assets 533
Total Current Assets  (as reported)61,762
Total Current Assets  (calculated)1,396
+/- 60,366
Long-term Assets
Property Plant Equipment 389
Intangible Assets 13,468
Long-term Assets  (as reported)14,875
Long-term Assets  (calculated)13,857
+/- 1,018

Liabilities & Shareholders' Equity

Total Current Liabilities32,109
Long-term Liabilities18,628
Total Stockholder Equity25,900
Total Current Liabilities
Short-term Debt 25,251
Accounts payable 4,603
Other Current Liabilities 2,255
Total Current Liabilities  (as reported)32,109
Total Current Liabilities  (calculated)32,109
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)18,628
Long-term Liabilities  (calculated)0
+/- 18,628
Total Stockholder Equity
Common Stock1,022,964
Other Stockholders Equity -997,064
Total Stockholder Equity (as reported)25,900
Total Stockholder Equity (calculated)25,900
+/-0
Other
Cash and Short Term Investments 863
Common Stock Shares Outstanding 1,022,949
Liabilities and Stockholders Equity 76,637
Net Debt 43,016
Net Working Capital 29,653
Short Long Term Debt Total 43,879



6.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302021-12-312021-06-302020-12-312020-06-302019-12-312019-06-302018-12-312018-06-302017-12-312017-06-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-30
> Total Assets 
0
0
75,705
0
74,944
73,644
497,261
501,916
501,291
503,142
507,761
527,930
513,979
519,465
503,849
499,619
395,402
327,729
251,239
213,789
175
51
123,971
123,744
124,017
126,556
126,255
125,889
125,742
126,310
86,300
126,584
80,838
77,087
80,838
72,375
57,582
58,124
63,645
67,436
0
71,072
92,188
85,625
83,408
81,335
78,281
76,637
76,63778,28181,33583,40885,62592,18871,072067,43663,64558,12457,58272,37580,83877,08780,838126,58486,300126,310125,742125,889126,255126,556124,017123,744123,97151175213,789251,239327,729395,402499,619503,849519,465513,979527,930507,761503,142501,291501,916497,26173,64474,944075,70500
   > Total Current Assets 
0
0
60,580
0
59,374
57,601
41,751
44,397
40,260
39,195
82,376
101,593
86,046
92,435
89,415
84,867
89,432
23,252
44,832
213,789
175
51
721
494
767
3,306
2,697
2,331
2,184
126,310
86,300
126,584
79,115
5,567
79,115
72,375
82
188
145
186
0
71,072
79,003
72,103
69,984
67,231
63,685
61,762
61,76263,68567,23169,98472,10379,00371,07201861451888272,37579,1155,56779,115126,58486,300126,3102,1842,3312,6973,30676749472151175213,78944,83223,25289,43284,86789,41592,43586,046101,59382,37639,19540,26044,39741,75157,60159,374060,58000
       Cash And Cash Equivalents 
0
0
7,698
0
4,961
2,816
3,947
6,560
3,721
3,151
2,820
64,642
50,536
54,128
53,522
2,627
3,410
22,475
20,742
5,169
11
10
2
1
1
1,187
376
171
1
1
3
1
1
5
1
0
0
0
0
74
0
182
12,079
3,512
1,475
4,231
2,199
863
8632,1994,2311,4753,51212,079182074000015113111713761,18711210115,16920,74222,4753,4102,62753,52254,12850,53664,6422,8203,1513,7216,5603,9472,8164,96107,69800
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
35,000
0
0
35,000
35,000
35,000
0
0
0
0
0
0
0
0
0
1,380
1,688
1,599
1,557
1,863
0
1,723
1,723
1,723
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000001,7231,7231,72301,8631,5571,5991,6881,38000000000035,00035,00035,0000035,0000000000000
       Net Receivables 
0
0
0
0
0
0
2,804
0
0
0
0
0
0
0
893
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
70,886
65,282
66,860
66,785
62,577
60,904
0
060,90462,57766,78566,86065,28270,8860000000000000000000000000089300000002,804000000
       Other Current Assets 
0
0
170
0
54,413
54,785
35,000
37,837
36,539
36,044
44,556
36,951
35,510
3,307
0
47,240
86,022
777
24,090
208,620
164
41
719
493
766
739
633
561
626
124,446
86,297
124,860
79,114
3,839
79,114
72,375
82
188
145
112
0
3
65,332
139
132
422
582
533
53358242213213965,332301121451888272,37579,1143,83979,114124,86086,297124,44662656163373976649371941164208,62024,09077786,02247,24003,30735,51036,95144,55636,04436,53937,83735,00054,78554,413017000
   > Long-term Assets 
0
0
15,125
0
15,570
16,043
455,510
457,519
461,031
463,947
425,385
426,337
427,933
427,030
414,434
414,752
305,970
304,477
206,407
0
0
0
123,250
123,250
123,250
123,250
123,558
123,558
123,558
0
0
0
1,723
71,520
0
0
57,500
57,936
63,500
67,250
0
14
13,185
13,522
13,424
14,105
14,596
14,875
14,87514,59614,10513,42413,52213,18514067,25063,50057,93657,5000071,5201,723000123,558123,558123,558123,250123,250123,250123,250000206,407304,477305,970414,752414,434427,030427,933426,337425,385463,947461,031457,519455,51016,04315,570015,12500
       Property Plant Equipment 
0
0
0
0
0
0
438,342
0
441,431
342,909
403,326
403,326
303,264
401,040
0
0
0
0
0
0
0
0
99,463
99,463
99,463
99,463
99,696
99,696
99,696
0
0
0
0
0
0
0
0
0
0
0
0
1
579
502
426
507
447
389
389447507426502579100000000000099,69699,69699,69699,46399,46399,46399,46300000000401,040303,264403,326403,326342,909441,4310438,342000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
14
12,071
11,815
11,558
13,598
0
13,468
13,468013,59811,55811,81512,0711400000000000000000000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
51
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-14
0
0
0
-1
0
0
00-1000-14000000000000000000051000000000000000000000
> Total Liabilities 
0
0
22,237
0
29,709
29,812
444,197
409,154
411,486
416,391
428,095
451,195
442,293
452,148
467,462
467,535
427,276
366,255
356,679
322,535
73,282
73,283
26,021
21,016
22,003
25,371
26,722
26,727
26,791
29,612
1,209
22,697
3,266
2,589
13,682
17,132
23,301
24,510
21,079
23,078
0
25,027
30,811
29,710
32,136
42,404
46,521
50,737
50,73746,52142,40432,13629,71030,81125,027023,07821,07924,51023,30117,13213,6822,5893,26622,6971,20929,61226,79126,72726,72225,37122,00321,01626,02173,28373,282322,535356,679366,255427,276467,535467,462452,148442,293451,195428,095416,391411,486409,154444,19729,81229,709022,23700
   > Total Current Liabilities 
0
0
12,181
0
1,703
1,453
11,012
8,196
11,089
10,550
102,140
62,107
63,638
50,142
27,459
6,386
68,079
10,138
206,404
322,535
73,282
73,283
3,943
4,134
4,869
8,995
9,811
9,816
9,880
29,612
1,209
22,697
3,266
2,589
5,241
7,132
23,301
21,607
14,497
16,332
0
25,027
30,590
29,586
31,086
34,332
30,504
32,109
32,10930,50434,33231,08629,58630,59025,027016,33214,49721,60723,3017,1325,2412,5893,26622,6971,20929,6129,8809,8169,8118,9954,8694,1343,94373,28373,282322,535206,40410,13868,0796,38627,45950,14263,63862,107102,14010,55011,0898,19611,0121,4531,703012,18100
       Short-term Debt 
0
0
0
0
1,703
1,453
0
0
0
0
0
0
44,435
0
6,123
0
0
0
172,118
21,363
72,125
72,393
15
1,090
1,436
6,746
6,298
5,065
5,105
5,505
103
1,409
1,486
1,000
1,662
3,634
10,041
8,339
12,343
13,902
0
22,841
21,047
21,385
21,617
22,149
23,187
25,251
25,25123,18722,14921,61721,38521,04722,841013,90212,3438,33910,0413,6341,6621,0001,4861,4091035,5055,1055,0656,2986,7461,4361,0901572,39372,12521,363172,1180006,123044,4350000001,4531,7030000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
16,652
0
3,796
0
26,082
1,012
0
0
2,859
0
0
0
3,513
4,751
4,775
4,382
1,106
918
1,780
1,589
3,453
3,456
3,260
3,268
654
1,430
0
2,186
9,013
6,748
6,743
10,202
5,376
4,603
4,6035,37610,2026,7436,7489,0132,18601,4306543,2683,2603,4563,4531,5891,7809181,1064,3824,7754,7513,5130002,859001,01226,08203,796016,65200000000000000
       Other Current Liabilities 
0
0
12,181
0
0
0
11,012
8,196
11,089
10,550
102,140
62,107
19,203
50,142
4,684
6,386
64,283
10,138
4,829
300,160
1,157
890
1,069
3,044
3,433
2,249
0
0
0
19,725
0
20,370
0
0
126
42
10,000
62
1,500
1,000
0
0
530
1,453
2,726
-68
1,941
2,255
2,2551,941-682,7261,453530001,0001,5006210,000421260020,370019,7250002,2493,4333,0441,0698901,157300,1604,82910,13864,2836,3864,68450,14219,20362,107102,14010,55011,0898,19611,01200012,18100
   > Long-term Liabilities 
0
0
10,056
0
28,006
28,359
433,185
400,958
400,397
405,841
325,955
389,088
378,655
402,006
440,003
461,149
359,197
356,117
150,275
0
0
73,283
22,078
16,882
17,134
16,376
16,911
16,911
16,911
0
0
0
0
0
8,441
10,000
0
2,903
6,582
6,746
0
0
221
124
1,050
8,072
16,017
18,628
18,62816,0178,0721,050124221006,7466,5822,903010,0008,4410000016,91116,91116,91116,37617,13416,88222,07873,28300150,275356,117359,197461,149440,003402,006378,655389,088325,955405,841400,397400,958433,18528,35928,006010,05600
> Total Stockholder Equity
0
0
46,764
0
45,235
43,832
53,064
92,762
89,805
86,751
79,666
76,735
71,686
67,317
36,387
32,084
-31,874
-38,526
-105,440
-108,746
-73,107
-73,232
97,690
97,256
96,542
95,713
94,917
94,546
94,335
93,062
85,091
102,015
77,572
74,498
67,156
55,243
34,281
33,614
42,566
44,358
0
46,045
61,377
55,915
51,272
38,931
31,760
25,900
25,90031,76038,93151,27255,91561,37746,045044,35842,56633,61434,28155,24367,15674,49877,572102,01585,09193,06294,33594,54694,91795,71396,54297,25697,690-73,232-73,107-108,746-105,440-38,526-31,87432,08436,38767,31771,68676,73579,66686,75189,80592,76253,06443,83245,235046,76400
   Common Stock
0
0
130,863
0
130,863
130,863
45,000
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
75,784
112,983
112,983
108,692
108,692
108,692
108,692
108,692
108,692
108,692
108,692
119,092
119,092
119,092
119,092
83,092
83,092
83,092
0
18,655
18,655
0
18,655
1,022,964
1,022,964
1,022,964
1,022,964
1,022,964
1,022,964
1,022,9641,022,9641,022,9641,022,9641,022,9641,022,96418,655018,65518,655083,09283,09283,092119,092119,092119,092119,092108,692108,692108,692108,692108,692108,692108,692108,692112,983112,98375,78475,78475,78475,78475,78475,78475,78475,78475,78475,78475,78475,78475,78445,000130,863130,8630130,86300
   Retained Earnings Total Equity000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
112,973
108,682
108,682
108,682
108,682
108,682
108,682
108,682
0
0
0
0
0
0
0
0
0
0
0
0
18
1,022,964
1,022,964
1,022,964
-984,033
-991,204
0
0-991,204-984,0331,022,9641,022,9641,022,96418000000000000108,682108,682108,682108,682108,682108,682108,682112,973000000000000000000000
   Capital Surplus 000000000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
-10
11,801
12,298
12,298
-10
-10
-10
-10
-10
-10
1,275
1,275
1,275
8,496
1,275
1,275
-108,692
-10
-10
-10
-108,692
-10
-10
-534
-534
-340
0
0
0
0
0
33,614
0
0
0
-18
-961,587
-967,049
-971,692
-984,033
-991,204
-997,064
-997,064-991,204-984,033-971,692-967,049-961,587-1800033,61400000-340-534-534-10-10-108,692-10-10-10-108,6921,2751,2758,4961,2751,2751,275-10-10-10-10-10-1012,29812,29811,801-10000000



6.3. Balance Sheets

All numbers in thousands.




6.4. Cash Flows

All numbers in thousands.




6.5. Income Statements

All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-09-30. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-480
Gross Profit-480-480
 
Operating Income (+$)
Gross Profit-480
Operating Expense-24,813
Operating Income-25,293-25,293
 
Operating Expense (+$)
Research Development9,082
Selling General Administrative12
Selling And Marketing Expenses15,719
Operating Expense24,81324,813
 
Net Interest Income (+$)
Interest Income0
Interest Expense-1,562
Other Finance Cost-1,562
Net Interest Income0
 
Pretax Income (+$)
Operating Income-25,293
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-26,841-23,745
EBIT - interestExpense = -26,841
-26,841
-23,047
Interest Expense1,562
Earnings Before Interest and Taxes (EBIT)-25,279-25,279
Earnings Before Interest and Taxes (EBITDA)-24,799
 
After tax Income (+$)
Income Before Tax-26,841
Tax Provision-0
Net Income From Continuing Ops0-26,841
Net Income-24,609
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses25,293
Total Other Income/Expenses Net-1,5480
 

Technical Analysis of Pharma Equity Group A/S Cl A
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Pharma Equity Group A/S Cl A. The general trend of Pharma Equity Group A/S Cl A is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Pharma Equity Group A/S Cl A's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Pharma Equity Group A/S Cl A.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 0.1795 < 0.187 < 0.1995.

The bearish price targets are: 0.15.

Tweet this
Pharma Equity Group A/S Cl A Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Pharma Equity Group A/S Cl A. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Pharma Equity Group A/S Cl A Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Pharma Equity Group A/S Cl A. The current macd is -0.01117854.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharma Equity Group A/S Cl A price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Pharma Equity Group A/S Cl A. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Pharma Equity Group A/S Cl A price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Pharma Equity Group A/S Cl A Daily Moving Average Convergence/Divergence (MACD) ChartPharma Equity Group A/S Cl A Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Pharma Equity Group A/S Cl A. The current adx is 26.93.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Pharma Equity Group A/S Cl A shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Pharma Equity Group A/S Cl A Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Pharma Equity Group A/S Cl A. The current sar is 0.18344507.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Pharma Equity Group A/S Cl A Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Pharma Equity Group A/S Cl A. The current rsi is 39.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Pharma Equity Group A/S Cl A Daily Relative Strength Index (RSI) ChartPharma Equity Group A/S Cl A Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Pharma Equity Group A/S Cl A. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Pharma Equity Group A/S Cl A price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Pharma Equity Group A/S Cl A Daily Stochastic Oscillator ChartPharma Equity Group A/S Cl A Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Pharma Equity Group A/S Cl A. The current cci is -68.57878286.

Pharma Equity Group A/S Cl A Daily Commodity Channel Index (CCI) ChartPharma Equity Group A/S Cl A Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Pharma Equity Group A/S Cl A. The current cmo is -15.25859496.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Pharma Equity Group A/S Cl A Daily Chande Momentum Oscillator (CMO) ChartPharma Equity Group A/S Cl A Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Pharma Equity Group A/S Cl A. The current willr is -72.97297297.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Pharma Equity Group A/S Cl A is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Pharma Equity Group A/S Cl A Daily Williams %R ChartPharma Equity Group A/S Cl A Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Pharma Equity Group A/S Cl A.

Pharma Equity Group A/S Cl A Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Pharma Equity Group A/S Cl A. The current atr is 0.00898683.

Pharma Equity Group A/S Cl A Daily Average True Range (ATR) ChartPharma Equity Group A/S Cl A Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Pharma Equity Group A/S Cl A. The current obv is 4,893,386.

Pharma Equity Group A/S Cl A Daily On-Balance Volume (OBV) ChartPharma Equity Group A/S Cl A Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Pharma Equity Group A/S Cl A. The current mfi is 38.21.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Pharma Equity Group A/S Cl A Daily Money Flow Index (MFI) ChartPharma Equity Group A/S Cl A Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Pharma Equity Group A/S Cl A.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-16DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-07-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-07-23MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-07-25STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-29CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-07-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-07-31STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-16STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-08-19BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-08-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-27CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-03WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-09STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-09-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-09-26STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-09-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-07CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-10-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-24STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-10-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-04MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-14SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-22WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-25STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Pharma Equity Group A/S Cl A Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Pharma Equity Group A/S Cl A based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.303
Ma 20Greater thanMa 500.165
Ma 50Greater thanMa 1000.197
Ma 100Greater thanMa 2000.235
OpenGreater thanClose0.160
Total0/5 (0.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Pharma Equity Group A/S Cl A with someone you think should read this too:
  • Are you bullish or bearish on Pharma Equity Group A/S Cl A? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Pharma Equity Group A/S Cl A? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Pharma Equity Group A/S Cl A

I send you an email if I find something interesting about Pharma Equity Group A/S Cl A.


Comments

How you think about this?

Leave a comment

Stay informed about Pharma Equity Group A/S Cl A.

Receive notifications about Pharma Equity Group A/S Cl A in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.